Quick Answer
Zura Bio Ltd reported Operating Income Loss of -$75.25 million for the year ending 2025.
- Zura Bio Ltd showed a decrease of -36.3% in Operating Income Loss from 2024 to 2025.
- This data is from Zura Bio Ltd's annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$33.0 thousand | Q2 2021: -$19.1 thousand | Q3 2021: -$321.9 thousand | Q1 2022: -$7.82 million | Q2 2022: -$927.0 thousand | Q3 2022: -$1.07 million | Q1 2023: -$7.72 million | Q2 2023: -$33.91 million | Q3 2023: -$10.19 million | Q1 2024: -$8.38 million | Q2 2024: -$11.76 million | Q3 2024: -$19.32 million | Q1 2025: -$19.25 million | Q2 2025: -$18.06 million | Q3 2025: -$19.52 million.
- Over the full 4 years of available data (2022 to 2025), Zura Bio Ltd's Operating Income Loss has declined by 177.0%.
- Historical annual values: Fiscal year 2025: -$75.25 million | Fiscal year 2024: -$55.19 million | Fiscal year 2023: -$62.64 million | Fiscal year 2022: -$27.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: